Selecta Russia's mission is to build a robust clinical pipeline of immunology related therapies consisting of Selecta's proprietary Synthetic Vaccine Particles (SVP™) technology and clinical stage compounds in-licensed from biotech and pharmaceutical companies. Our activities in Russia support Selecta Biosciences' goals of expanding its portfolio of immunotherapies and accelerating its clinical development, while recognizing the specific requirements of Russian patients. Selecta Russia R&D programs are developed in close coordination with Selecta in Boston.
The establishment of Selecta in Russia is aligned with the Russian Government's Pharma 2020 efforts to support local companies to develop and produce innovative medicines and provide access to the latest therapies for the benefit of patients both in Russia and worldwide. Selecta Russia has built a network of partners in governmental organization and Russian pharmaceutical companies.
Selecta Russia has focused on recruiting a world-class team with scientists hired from top tier pharmaceutical companies and academic institutions. The team has built a full-fledged R&D facility and initiated work on several programs for Selecta’s stimulatory vaccine platform and has built manufacturing capacity to produce laboratory supply of stimulatory SVP™ nanoparticles. The company is collaborating with the Russian government and research foundations and has been successful in securing funding for Selecta’s stimulatory vaccines program.
Selecta Russia is a wholly-owned subsidiary of Selecta Biosciences, Inc. and was founded in 2011 as a result of Selecta’s partnership with Rusnano.